Effect of metformin/irinotecan-loaded poly-lactic-co-glycolic acid nanoparticles on glioblastoma: in vitro and in vivo studies

TAGHIZADEHGHALEHJOUGHI A., HACIMÜFTÜOĞLU A., ÇETİN M., UĞUR A. B., GALATEANU B., MEZHUEV Y., ...More

NANOMEDICINE, vol.13, no.13, pp.1595-1606, 2018 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 13 Issue: 13
  • Publication Date: 2018
  • Doi Number: 10.2217/nnm-2017-0386
  • Journal Name: NANOMEDICINE
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1595-1606
  • Keywords: brain tumor, Cavalieri's principle, irinotecan, metformin, nanoparticles, PLGA, IRINOTECAN CPT-11, METFORMIN, CANCER, GROWTH, CELL, THERAPY, GLIOMA, ZINGIBERENE, MULTIFORME, CARCINOMA
  • Ataturk University Affiliated: Yes

Abstract

Aim: The present study was designed to evaluate the effects of irinotecan hydrochloride (IRI)- or metformin hydrochloride (MET)-loaded poly-lactic-co-glycolic acid (PLGA) nanoparticles (NPs) for the treatment of glioblastoma multiforme using in vitro neuron and U-87 MG glioblastoma cell cultures and in vivo animal model. Methods: The cytotoxic and neurotoxic effects of pure drugs, blank NPs and MET- and IRI-loaded PLGA NPs were investigated in vitro (using methylthiazolyldiphenyl-tetrazolium bromide assay) and in vivo (using Cavalieri's principle for estimation of cancer volume). Results: 1 and 2 mM doses of MET and MET-loaded PLGA NPs, respectively, significantly reduced the volume of extracted cancer. Conclusion: Consequently, MET- and IRI-loaded PLGA NPs may be a promising approach for the treatment of glioblastoma multiforme.